KR20240101629A9 - Cd137을 표적화하는 이중특이적 항체 및 항암 면역요법을 위한 이의 용도 - Google Patents
Cd137을 표적화하는 이중특이적 항체 및 항암 면역요법을 위한 이의 용도Info
- Publication number
- KR20240101629A9 KR20240101629A9 KR1020247018465A KR20247018465A KR20240101629A9 KR 20240101629 A9 KR20240101629 A9 KR 20240101629A9 KR 1020247018465 A KR1020247018465 A KR 1020247018465A KR 20247018465 A KR20247018465 A KR 20247018465A KR 20240101629 A9 KR20240101629 A9 KR 20240101629A9
- Authority
- KR
- South Korea
- Prior art keywords
- bispecific antibody
- antibody targeting
- anticancer immunotherapy
- immunotherapy
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163281347P | 2021-11-19 | 2021-11-19 | |
| US63/281,347 | 2021-11-19 | ||
| US202263392474P | 2022-07-26 | 2022-07-26 | |
| US63/392,474 | 2022-07-26 | ||
| PCT/US2022/050472 WO2023091712A1 (en) | 2021-11-19 | 2022-11-18 | Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20240101629A KR20240101629A (ko) | 2024-07-02 |
| KR20240101629A9 true KR20240101629A9 (ko) | 2025-12-10 |
Family
ID=86397821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247018465A Pending KR20240101629A9 (ko) | 2021-11-19 | 2022-11-18 | Cd137을 표적화하는 이중특이적 항체 및 항암 면역요법을 위한 이의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250026841A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4433511A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540604A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240101629A9 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022389917A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3237165A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312715A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005999A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023091712A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2438442B1 (en) * | 2008-12-01 | 2017-08-09 | Laboratory Corporation of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| US20100233732A1 (en) * | 2009-01-15 | 2010-09-16 | Laboratory Corporation Of America Holdings | Methods of Determining Patient Response By Measurement of HER-2 Expression |
| MX2018015022A (es) * | 2016-06-07 | 2019-08-14 | Biogen Int Neuroscience Gmbh | Métodos para el tratamiento de la enfermedad de alzheimer. |
| CN109843926B (zh) * | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | 针对cd3的双特异性抗体 |
| BR112021026309A2 (pt) * | 2019-06-26 | 2022-06-07 | Ap Biosciences Inc | Anticorpos para ativação de células t |
| CN118638240A (zh) * | 2019-07-26 | 2024-09-13 | 柳韩洋行 | 抗her2/抗4-1bb双特异性抗体及其用途 |
| KR20220145859A (ko) * | 2020-02-28 | 2022-10-31 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물, 다중 특이적 항체 및 그 용도 |
| JP2023517234A (ja) * | 2020-03-09 | 2023-04-24 | アブセレラ バイオロジクス インコーポレイテッド | 抗コロナウイルス抗体および使用の方法 |
-
2022
- 2022-11-18 CA CA3237165A patent/CA3237165A1/en active Pending
- 2022-11-18 EP EP22896552.1A patent/EP4433511A4/en active Pending
- 2022-11-18 KR KR1020247018465A patent/KR20240101629A9/ko active Pending
- 2022-11-18 JP JP2024529917A patent/JP2024540604A/ja active Pending
- 2022-11-18 WO PCT/US2022/050472 patent/WO2023091712A1/en not_active Ceased
- 2022-11-18 IL IL312715A patent/IL312715A/en unknown
- 2022-11-18 US US18/708,551 patent/US20250026841A1/en active Pending
- 2022-11-18 MX MX2024005999A patent/MX2024005999A/es unknown
- 2022-11-18 AU AU2022389917A patent/AU2022389917A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250026841A1 (en) | 2025-01-23 |
| AU2022389917A1 (en) | 2024-05-23 |
| JP2024540604A (ja) | 2024-10-31 |
| KR20240101629A (ko) | 2024-07-02 |
| EP4433511A1 (en) | 2024-09-25 |
| MX2024005999A (es) | 2024-05-30 |
| IL312715A (en) | 2024-07-01 |
| CA3237165A1 (en) | 2023-05-25 |
| EP4433511A4 (en) | 2026-02-11 |
| WO2023091712A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2595980B (en) | Anti-TCR antibody molecules and uses thereof | |
| PT3802608T (pt) | Anticorpos anti-cd3 e utilizações destes | |
| SG11202010443WA (en) | Compositions and methods related to anti-cd19 antibody drug conjugates | |
| IL289354A (en) | Anti-cd154 antibodies and uses thereof | |
| DK4067387T3 (da) | Bispecifikt anti-pd-1-anti-vegfa-antistof, farmaceutisk sammensætning og anvendelse deraf | |
| IL265330A (en) | Anti-steap2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Compounds That Bind Steap2 and CD3, and Their Uses | |
| IL286483A (en) | Claudin-6 antibodies and drug conjugates | |
| SI3599251T1 (sl) | Konstrukcija kimernega antigenskega receptorja, ciljnega na antigen CD20, in identifikacija aktivnosti njegovih inženiriranih T-celic | |
| PL3458479T4 (pl) | Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek | |
| EP3411069A4 (en) | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREFOR | |
| DK3328892T3 (da) | Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3 | |
| GB2607452B (en) | Anti-TCR antibody molecules and uses thereof | |
| IL282610B (en) | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
| IL247936A0 (en) | Antibodies against egfr and drug antibody conjugates | |
| DK3380122T3 (da) | Anti-5t4 antistoffer og antistoflægemiddel konjugater | |
| MX377297B (es) | Anticuerpos tem8 y su uso. | |
| SI2897981T1 (sl) | Protitelesa proti-CD3,bispecifične molekule,ki vežejo antigen,ki vežejo CD3 in CD20 in njihove uporabe | |
| SG11202112223XA (en) | Antibody drug conjugates | |
| EP3858384A4 (en) | COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS | |
| IL287690A (en) | Anti-hvem antibodies and use thereof | |
| DK3561057T3 (da) | Anti-cd3-antistof og molekyle indeholdende nævnte antistof | |
| EP4051711A4 (en) | ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES | |
| IL281076A (en) | Anti-cd3 antibody folate bioconjugates and their uses | |
| IL289488A (en) | Monoclonal antibodies that bind egfrviii and their use | |
| SI3455261T1 (sl) | Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P19 | Errors in documents containing ipogçös decisions corrected |
Free format text: ST27 STATUS EVENT CODE: A-3-3-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PG1701 | Publication of correction |
St.27 status event code: A-3-3-P10-P19-oth-PG1701 Patent document republication publication date: 20251210 Republication note text: Request for Correction Notice (Document Request) Gazette number: 1020240101629 Gazette reference publication date: 20240702 |